Contraception
Volume 75, Issue 1 , Pages 40-44 , January 2007

Weekly contraception with mifepristone

  • Kaiyan Pei

      Affiliations

    • Department of Reproductive Endocrinology, National Research Institute for Family Planning, Hai Dian District, Beijing 100081, PR China
    • Corresponding Author InformationCorresponding author.
    • ,
  • Bilian Xiao

      Affiliations

    • Department of Reproductive Endocrinology, National Research Institute for Family Planning, Hai Dian District, Beijing 100081, PR China
    • ,
  • Xiaoping Jing

      Affiliations

    • Department of Gynecology and Obstetrics, Beijing Chaoyang Hospital, Beijing 100020, PR China
    • ,
  • Shengqun Lu

      Affiliations

    • Department of Gynecology and Obstetrics, The Third Affiliated Hospital of Inner Mongolia Medical College, Baotou 014010, PR China
    • ,
  • Ling Wei

      Affiliations

    • Department of Gynecology and Obstetrics, Beijing Chaoyang Hospital, Beijing 100020, PR China
    • ,
  • Heng Zhao

      Affiliations

    • Department of Reproductive Endocrinology, National Research Institute for Family Planning, Hai Dian District, Beijing 100081, PR China

Received 17 May 2006 ,Revised 23 August 2006 ,Accepted 31 August 2006.

References 

  1. Marions L, Danielsson KG, Swahn ML, et al. Contraceptive efficacy of low doses of mifepristone. Fertil Steril. 1998;70:813–816
  2. Cheng J, Weng L, Han X, Xiao B. Study on weekly low doses of mifepristone for contraception. Zhonghua Fu Chan Ke Za Zhi. 2001;36:424–427[Chinese]
  3. Godfrey EM, Mawson JT, Stanwood NL, Fielding SL, Schaff EA. Low-dose mifepristone for contraception: a weekly versus planned postcoital randomized pilot study. Contraception. 2004;70:41–46
  4. Chen X, Xiao B. Effect of once weekly administration of mifepristone on ovarian function in normal women. Contraception. 1997;56:175–180
  5. Spitz IM, Croxatto HB, Salvatierra AM, Heikinheimo O. Response to intermittent RU486 in women. Fertil Steril. 1993;59:971–975
  6. Danforth DR, Williams RF, Hsiu JG, et al. Intermittent GnRH antagonist plus progestin contraception conserving tonic ovarian estrogen secretion and reducing progestin exposure. Contraception. 1990;41:623–631
  7. Singh MM. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. Med Res Rev. 2001;21:302–347
  8. Lal J, Nitynand S, Asthana OP, Nagaraja NV, Gupta RC. Optimization of contraceptive dosage regimen of Centchroman. Contraception. 2001;63:47–51
  9. Potter L, Oakley D, de Leon-Wong E, Canamar R. Measuring compliance among oral contraceptive users. Fam Plann Perspect. 1996;28:154–158
  10. David SS, Huggins GR, Garcia CR, Busacca C. A synthetic steroid (R2323) as a once-a-week oral contraceptive. Fertil Steril. 1979;31:278–281
  11. Bartl R, Gotte S, Hadji P, Hammerschmidt T. Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment. Dtsch Med Wochenschr. 2006;131:1257–1262
  12. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc. 2005;80:856–861

PII: S0010-7824(06)00354-4

doi: 10.1016/j.contraception.2006.08.013

Contraception
Volume 75, Issue 1 , Pages 40-44 , January 2007

Article Tools

* Image Usage & Resolution